Cardiovascular Medicine Brigham and Women's Hospital
Cardiology
Dr. Robert P. Giugliano, MD
|
|
Give Review
Robert Giugliano practices Cardiology. He attended Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School has a rank of 1 in research and a 12 in primary care He has 1 awards "Fellow (FACC)". Doctor Robert P. Giugliano, MD is a published doctor and has 94 publications published. The lastest was: 'Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment Elevation Acute Coronary Syndromes Clinical Trials.' Robert P. Giugliano accepts Medicare.
Publications
- Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular Atrial fibrillation.
- Influence of proven oral therapies in the very old with Acute coronary syndromes: A 15 year experience.
- EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing Primary pe...
- Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation Acute coronary syndromes patients with left circumflex culprit...
- Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
- Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
- Prognostic Implications of Low Level Cardiac Troponin Elevation Using High-Sensitivity Cardiac Troponin T.
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events.
- Editors' Picks for 2014 and a Look into the Future.
- Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with Atrial fibrillationâ
- Selecting an oral anticoagulant for patients with nonvalvular Atrial fibrillation.
- Impact of Time of Presentation on Process Performance and Outcomes in ST-Segment-Elevation Myocardial Infarction: A Report From the American Heart Association: Mission...
- Genotype-guided dosing of warfarin.
- New oral anticoagulants in patients with Atrial fibrillation - Authors'reply.
- Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in ...
- Erratum to: Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Impli...
- Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled anal...
- Edoxaban: Review of Pharmacology and Key Phase I to III Clinical Trials.
- The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
- Edoxaban or standard therapy with warfarin for stroke prevention in patients with Atrial fibrillation?
- AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Program-Adult Treatment Panel III Low-Density Lipoprotein Chole...
- Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for ...
- Angiographic Outcomes With Early Eptifibatide Therapy in Non-ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial).
- Clinical Implications and Correlates of Q Waves in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the CLARITY-TIMI 28 Tr...
- Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials.
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with Atrial fibrillation: a meta-analysis of randomised trials.
- Left Atrial structure and function in Atrial fibrillation: ENGAGE AF-TIMI 48.
- Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with fibrin-specific anticoagulants.
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation.
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term...
- The Year in Acute Coronary Syndrome.
- Age, treatment, and outcomes in high-risk non-ST-segment elevation Acute coronary syndrome patients: Insights from the EARLY ACS trial.
- Emerging antithrombotic drugs for Acute coronary syndrome.
- Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition: A Post Hoc Analysis of the TRITON-TIMI 38 Trial.
- AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving St...
- The P-glycoprotein transport system and cardiovascular drugs.
- Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation Acute coronary syndrome.
- Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies.
- Cardiac Troponin after Percutaneous Coronary Intervention and 1-Year Mortality in NSTE ACS Using Systematic Evaluation of Biomarker Trends.
- Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation Acute coronary syndromes.
- Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of in...
- Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes: Incidence, Angiographic Characteristics, and Clinical Outcomes.
- Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.
- Relation Between Time of Symptom Onset of ST-Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry.
- The Year in Non-ST-Segment Elevation Acute Coronary Syndrome.
- Association Between Angiographic Complications and Clinical Outcomes Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An EARL...
- Niacin at 56 Years of Age - Time for an Early Retirement?
- Safety and efficacy of adjusted-dose eptifibatide in patients with Acute coronary syndromes and reduced renal function.
- In Patients With Acute Myocardial Infarction, the Impact of Hyperglycemia as a Risk Factor for Mortality Is Not Homogeneous Across Age-Groups.
- Bridging therapy after recent stent implantation: case report and review of data.
- The facts behind niacin.
- Dabigatran: a review of clinical and pharmacoeconomic evidence.
- Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized...
- Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizi...
- Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine.
- Effectiveness and safety of percutaneous coronary intervention after fibrinolytic therapy for ST-segment elevation Acute myocardial infarction.
- Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an...
- Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with Acute coronary syndrome: an analysis from the Early Glycoprotein ...
- ED to catheterization laboratory: a roundtable integrating trials with practice.
- Prior aspirin use and outcomes in Acute coronary syndromes.
- Novel biomarkers in cardiovascular Disease: update 2010.
- Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with Atrial fibrillation: design and rationale for the Effective aNticoaGulatio...
- Perspectives on the 2009 focused updates on the management of ST-segment elevation Myocardial infarction and percutaneous intervention.
- An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
- Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.
- Antithrombotics in Acute coronary syndromes: updates from the past year.
- Day 1 care in patients with non-ST-segment elevation Myocardial infarction.
- Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation Myocardial infarction.
- Management of ST-segment elevation Myocardial infarction: Comparison of the updated guidelines from North America and Europe.
- Antithrombotics in Acute coronary syndromes.
- Early versus delayed, provisional eptifibatide in Acute coronary syndromes.
- Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and Heart failure in patients with ST-elevation myocardial infarction in the TIMI ...
- Clinical problem-solving. When past is prologue.
- Antiplatelet therapy in percutaneous Coronary intervention: integration of prasugrel into clinical practice.
- Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation Acute coronary syndromes: principles and practices.
- Takayasu arteritis in a young woman: a 4-year case history.
- Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monoth...
- Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvasta...
- Antiplatelet therapy in early management of non-ST-segment elevation Acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe.
- Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with Acute coronary syndromes.
- Prognostic value of SPECT Myocardial perfusion imaging in patients with elevated cardiac troponin I levels and atypical clinical presentation.
- The year in non-ST-segment elevation Acute coronary syndromes.
- The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation Myocardial infarction: the ECG CLARITY-TIMI 28 Study.
- Comparison of long-term mortality across the spectrum of Acute coronary syndromes.
- Usefulness of the TIMI Risk Index in predicting short- and long-term mortality in patients with Acute coronary syndromes.
- Association of hemoglobin levels with clinical outcomes in Acute coronary syndromes.
- Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
- Association of smoking with improved Myocardial perfusion and the angiographic characterization of Myocardial tissue perfusion after fibrinolytic therapy for ST-segmen...
- Angiography and revascularization in patients with Heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction.
- Baseline troponin in Acute coronary syndromes managed invasively.
- Performance of the thrombolysis in Myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality ...
- Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment Elevation Acute Coronary Syndromes Clinical Trials.
- Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
Schools
Harvard Medical School
Cedars Sinai Mc
Brigham and Women39s Hospital
Mass Genl Hospital Harvard Med School
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Fellow (FACC)
Education
-
Massachusetts General Hospital -
Cedars-Sinai Medical Center -
Harvard Medical School
Hospital
-
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1255383048 | |
| NPPES Provider LastName | GIUGLIANO | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 640.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255383048 |
| Last Name Of The Provider | GIUGLIANO |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Michael H. Picard, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ming Hui Chen, MD |
|
|
Dr. Campbell K. Rogers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin M. Alexander, MD |
|
|
Dr. Laura Nasrallah, MD |
|
|
Dr. Kathryn A. Britton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos A. Montes, MD |
|
|
Dr. Robb D. Kociol, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amjad Almahameed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen E. Joynt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter H. Stone, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter G. Sanchez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noyan A. Gokce, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Natesa G. Pandian, MD |
|
|
Dr. Hsu-Ko Kuo, MD |